To investigate the potential role of SNX1 in modulating chemosensitivity in ovarian cancer, drug response prediction analysis was performed for multiple chemotherapeutic agents, including 5-fluorouracil, docetaxel, paclitaxel, cisplatin, and oxaliplatin. Here, SNX1 is linked to ovarian cancer.